Neuroprotective effect of thalidomide on MPTP-induced toxicity

• DOI: 10.1016/j.neuro.2015.02.004
• Publication Date: 2015-02-24T23:37:58Z
• Authors: Guadalupe Palencia; Esperanza Garcia; Laura Osorio-Rico; Cristina Trejo-Solís; Angel Escamilla-R...; Julio Sotelo
• Keywords: Male; Dopamine; Corpus Striatum; Thalidomide; 3. Good health; Mice, Inbred C57BL; Substantia Nigra; Mice; 03 medical and health sciences; Neuroprotective Agents; 0302 clinical medicine; Parkinsonian Disorders; Animals; Monoamine Oxidase

Thalidomide is a sedative with unique pharmacological properties; studies on epilepsy and brain ischemia have shown intense neuroprotective effects. We analyzed the effect of thalidomide treatment on the neurotoxicity caused by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahidropyridine (MPTP) in mice. Thalidomide was administered at two times; before and after the exposure to MPTP. In both circumstances thalidomide improved the neurotoxicity induced by MPTP as seen by a significant raise of the striatal contents of dopamine and simultaneous decrease of monoamine-oxidase-B (MAO-B). These results indicate that in the experimental model of Parkinson's disease the administration of thalidomide improves the functional damage on the nigrostriatal cell substratum as seen by the production of dopamine. This neuroprotective effect seems to be mediated by inhibition of excitotoxicity. Our results suggest that thalidomide could be investigated as potential adjuvant therapy for Parkinson's disease.